Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

              Author:Robertson, Derrick   Hartung, Hans-Peter   Arnold, Douglas   Lee, Lily   Gocke, Anne   Mok, Koby   Alvarez, Enrique   

              Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

              Topic:Multiple Sclerosis  

              Program Number:P9.017  

              Author Institution:University of South Florida, Tampa, FL  Heinrich Heine University Medical Faculty , Dusseldorf, Germany  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  TG Therapeutics, New York, NY  TG Therapeutics, Seal Beach, CA  University of Colorado, Aurora, CO